Ascendis Pharma A (ASND) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to -$73.1 million.
- Ascendis Pharma A's Income towards Parent Company fell 16713.68% to -$73.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$168.3 million, marking a year-over-year decrease of 16142.29%. This contributed to the annual value of -$409.2 million for FY2024, which is 2144.78% up from last year.
- Ascendis Pharma A's Income towards Parent Company amounted to -$73.1 million in Q3 2025, which was down 16713.68% from $45.6 million recorded in Q2 2025.
- Over the past 5 years, Ascendis Pharma A's Income towards Parent Company peaked at $176.6 million during Q3 2023, and registered a low of -$211.6 million during Q4 2022.
- Over the past 5 years, Ascendis Pharma A's median Income towards Parent Company value was -$75.7 million (recorded in 2021), while the average stood at -$28.3 million.
- Per our database at Business Quant, Ascendis Pharma A's Income towards Parent Company crashed by 25224.72% in 2023 and then surged by 21873.17% in 2024.
- Quarter analysis of 5 years shows Ascendis Pharma A's Income towards Parent Company stood at -$121.3 million in 2021, then plummeted by 74.41% to -$211.6 million in 2022, then surged by 55.07% to -$95.1 million in 2023, then surged by 56.77% to -$41.1 million in 2024, then plummeted by 77.92% to -$73.1 million in 2025.
- Its Income towards Parent Company was -$73.1 million in Q3 2025, compared to $45.6 million in Q2 2025 and -$99.6 million in Q1 2025.